TY - JOUR
T1 - Risk of subsequent bone cancers among 69 460 five-year survivors of childhood and adolescent cancer in Europe
AU - Fidler, Miranda M.
AU - Reulen, Raoul C.
AU - Winter, David L.
AU - Allodji, Rodrigue S.
AU - Bagnasco, Francesca
AU - Bardi, Edit
AU - Bautz, Andrea
AU - Bright, Chloe J.
AU - Byrne, Julianne
AU - Feijen, Elizabeth A.M.
AU - Garwicz, Stanislaw
AU - Grabow, Desiree
AU - Gudmundsdottir, Thorgerdur
AU - Guha, Joyeeta
AU - Haddy, Nadia
AU - Jankovic, Momcilo
AU - Kaatsch, Peter
AU - Kaiser, Melanie
AU - Kuonen, Rahel
AU - Linge, Helena
AU - Hawkins, Michael M.
N1 - Publisher Copyright:
© The Author 2017.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Introduction: We investigate the risks of subsequent primary bone cancers after childhood and adolescent cancer in 12 European countries. For the first time, we satisfactorily address the risks beyond 40 years from diagnosis and beyond 40 years of age among all survivors. Methods: This largest-ever assembled cohort comprises 69 460 five-year survivors of cancer diagnosed before age 20 years. Standardized incidence ratios, absolute excess risks, and multivariable-adjusted relative risks and relative excess risks were calculated. All statistical tests were two-sided. Results: Overall, survivors were 21.65 times (95% confidence interval ¼ 18.97 to 24.60 times) more likely to be diagnosed with a subsequent primary bone cancer than expected from the general population. The greatest excess numbers of bone cancers were observed after retinoblastoma, bone sarcoma, and soft tissue sarcoma. The excess number of bone cancers declined linearly with both years since diagnosis and attained age (all P < .05). Beyond 40 years from diagnosis and age 40 years, there were at most 0.45 excess bone cancers among all survivors per 10 000 person-years at risk; beyond 30 years from diagnosis and age 30 years, there were at most 5.02 excess bone cancers after each of retinoblastoma, bone sarcoma, and soft tissue sarcoma, per 10 000 person-years at risk. Conclusions: For all survivors combined and the cancer groups with the greatest excess number of bone cancers, the excess numbers observed declined with both age and years from diagnosis. These results provide novel, reliable, and unbiased information about risks and risk factors among long-term survivors of childhood and adolescent cancer.
AB - Introduction: We investigate the risks of subsequent primary bone cancers after childhood and adolescent cancer in 12 European countries. For the first time, we satisfactorily address the risks beyond 40 years from diagnosis and beyond 40 years of age among all survivors. Methods: This largest-ever assembled cohort comprises 69 460 five-year survivors of cancer diagnosed before age 20 years. Standardized incidence ratios, absolute excess risks, and multivariable-adjusted relative risks and relative excess risks were calculated. All statistical tests were two-sided. Results: Overall, survivors were 21.65 times (95% confidence interval ¼ 18.97 to 24.60 times) more likely to be diagnosed with a subsequent primary bone cancer than expected from the general population. The greatest excess numbers of bone cancers were observed after retinoblastoma, bone sarcoma, and soft tissue sarcoma. The excess number of bone cancers declined linearly with both years since diagnosis and attained age (all P < .05). Beyond 40 years from diagnosis and age 40 years, there were at most 0.45 excess bone cancers among all survivors per 10 000 person-years at risk; beyond 30 years from diagnosis and age 30 years, there were at most 5.02 excess bone cancers after each of retinoblastoma, bone sarcoma, and soft tissue sarcoma, per 10 000 person-years at risk. Conclusions: For all survivors combined and the cancer groups with the greatest excess number of bone cancers, the excess numbers observed declined with both age and years from diagnosis. These results provide novel, reliable, and unbiased information about risks and risk factors among long-term survivors of childhood and adolescent cancer.
UR - http://www.scopus.com/inward/record.url?scp=85030621565&partnerID=8YFLogxK
U2 - 10.1093/jnci/djx165
DO - 10.1093/jnci/djx165
M3 - Article
C2 - 28954302
AN - SCOPUS:85030621565
SN - 0027-8874
VL - 110
SP - 183
EP - 194
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 2
ER -